DBV Technologies (NASDAQ: DBVT) is one of 89 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare DBV Technologies to similar businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and earnings.
Volatility and Risk
DBV Technologies has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, DBV Technologies’ competitors have a beta of 1.59, suggesting that their average stock price is 59% more volatile than the S&P 500.
Institutional & Insider Ownership
39.5% of DBV Technologies shares are held by institutional investors. Comparatively, 49.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.6% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a summary of recent ratings for DBV Technologies and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DBV Technologies Competitors||450||1672||4482||148||2.64|
DBV Technologies presently has a consensus target price of $48.86, suggesting a potential upside of 104.08%. As a group, “Biological products, except diagnostic” companies have a potential upside of 21.28%. Given DBV Technologies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe DBV Technologies is more favorable than its competitors.
This table compares DBV Technologies and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DBV Technologies Competitors||-5,580.66%||-62.18%||-25.06%|
Earnings & Valuation
This table compares DBV Technologies and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|DBV Technologies||$13.46 million||-$166.93 million||-9.24|
|DBV Technologies Competitors||$1.05 billion||$96.04 million||1.43|
DBV Technologies’ competitors have higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
DBV Technologies Company Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohn's disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.